|Day Low/High||1.88 / 2.00|
|52 Wk Low/High||1.35 / 9.60|
Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and metastatic liver cancers, announces that results from two single-institution...
Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective Analysis
Againsttheodds.eu Recognized for High Quality Consumer Health Content
Proceeds expected to fund operations through year-end 2017
Growing Adoption of CHEMOSAT Permits Expansion Outside of European Union
Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical Development
Moffitt Cancer Center Begins Patient Enrollment in FOCUS Trial; Study Results to Support U.S. New Drug Application
Agreement Provides Regulatory Pathway for Melphalan/HDS with a Single Phase 3 Trial; Satisfies Substantial Number of Requirements in FDA's September 2013 Complete Response Letter
First Review of Current Product and Procedure to be used in the Planned Global Phase 3 Trial